Lung Cancer
Volume 66, Issue 3 , Pages 359-364 , December 2009

Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer

  • Joo Hun Park

      Affiliations

    • Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Youngtong-gu, Suwon, 443-721, South Korea
    • These authors contributed equally to this study.
    • ,
  • Ho Choi

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Ajou University School of Medicine, Suwon, South Korea
    • These authors contributed equally to this study.
    • ,
  • Young Bae Kim

      Affiliations

    • Department of Pathology, Ajou University School of Medicine, Suwon, South Korea
    • ,
  • Young Sun Kim

      Affiliations

    • Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Youngtong-gu, Suwon, 443-721, South Korea
    • ,
  • Seung Soo Sheen

      Affiliations

    • Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Youngtong-gu, Suwon, 443-721, South Korea
    • ,
  • Jin-Hyuk Choi

      Affiliations

    • Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, South Korea
    • ,
  • Hye Lim Lee

      Affiliations

    • Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Youngtong-gu, Suwon, 443-721, South Korea
    • ,
  • Keu Sung Lee

      Affiliations

    • Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Youngtong-gu, Suwon, 443-721, South Korea
    • ,
  • Woo Young Chung

      Affiliations

    • Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Youngtong-gu, Suwon, 443-721, South Korea
    • ,
  • Sungsoo Lee

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Ajou University School of Medicine, Suwon, South Korea
    • ,
  • Kyung Joo Park

      Affiliations

    • Department of Radiology, Ajou University School of Medicine, Suwon, South Korea
    • ,
  • Sung Chul Hwang

      Affiliations

    • Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Youngtong-gu, Suwon, 443-721, South Korea
    • ,
  • Kyi Beum Lee

      Affiliations

    • Department of Pathology, Ajou University School of Medicine, Suwon, South Korea
    • ,
  • Kwang Joo Park

      Affiliations

    • Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Youngtong-gu, Suwon, 443-721, South Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 31 219 5121; fax: +82 31 219 5124.

Received 5 December 2008 ,Revised 12 February 2009 ,Accepted 1 March 2009.

References 

  1. Scagliotti G. Consensus development conference on the medical treatment of non-small cell lung cancer: treatment of the early stages. Lung Cancer. 2002;38(Suppl. 3):S23–S29
  2. Ost D, Goldberg J, Rolnitzky L, Rom WN. Survival after surgery in stage IA and IB non-small cell lung cancer. Am J Respir Crit Care Med. 2008;177:516–523
  3. Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol. 2007;25:5562–5569
  4. Muley T, Fetz TH, Dienemann H, Hoffmann H, Herth FJ, Meister M, et al. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC. Lung Cancer. 2008;60:408–415
  5. Suzuki K, Nagai K, Yoshida J, Moriyama E, Nishimura M, Takahashi K, et al. Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg. 1999;67:927–932
  6. Angeletti CA, Lucchi M, Fontanini G, Mussi A, Chella A, Ribechini A, et al. Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence. Cancer. 1996;78:409–415
  7. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O’Byrne K, Scott PA, et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res. 1998;4:3017–3024
  8. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2006;51:143–158
  9. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671–674
  10. Shim WS, Ho IA, Wong PE. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res. 2007;5:655–665
  11. Yilmaz A, Ernam D, Unsal E, Demirag F, Atikcan S, Tastepe I. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer. Arch Med Res. 2007;38:764–768
  12. Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer. 2006;53:91–96
  13. Peters KG. Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel. Circ Res. 1998;83:342–343
  14. Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J Pathol. 2004;204:1–10
  15. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171–1180
  16. Hayes AJ, Huang WQ, Mallah J, Yang D, Lippman ME, Li LY. Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res. 1999;58:224–237
  17. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999;286:2511–2514
  18. Hawighorst T, Skobe M, Streit M, Hong YK, Velasco P, Brown LF, et al. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol. 2002;160:1381–1392
  19. Wong MP, Chan SY, Fu KH, Leung SY, Cheung N, Yuen ST, et al. The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer. 2000;29:11–22
  20. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55–60
  21. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284:1994–1998
  22. Takahama M, Tsutsumi M, Tsujiuchi T, Nezu K, Kushibe K, Taniguchi S, et al. Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin Cancer Res. 1999;5:2506–2510
  23. Takanami I. Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis. Oncol Rep. 2004;12:849–853
  24. Tanaka F, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M, et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res. 2002;62:7124–7129
  25. Caine GJ, Blann AD, Stonelake PS, Ryan P, Lip GY. Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest. 2003;33:883–890
  26. Niedzwiecki S, Stepien T, Kopec K, Kuzdak K, Komorowski J, Krupinski R, et al. Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers. Cytokine. 2006;36:291–295
  27. Schliemann C, Bieker R, Thoennissen N, Gerss J, Liersch R, Kessler T, et al. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia. 2007;21:1901–1906
  28. Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, Lee HN, et al. Serum angiopoietin-2 as a clinical marker for lung cancer. Chest. 2007;132:200–206
  29. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol. 1998;153:1459–1466
  30. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 2001;61:445–451
  31. Wang J, Wu K, Zhang D, Tang H, Xie H, Hong L, et al. Expressions and clinical significances of angiopoietin-1,-2 and Tie2 in human gastric cancer. Biochem Biophys Res Commun. 2005;337:386–393
  32. Currie MJ, Gunningham SP, Han C, Scott PA, Robinson BA, Harris AL, et al. Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling. Clin Cancer Res. 2001;7:918–927
  33. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710–1717
  34. Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, Risau W. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol. 1998;8:529–532
  35. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest. 1999;79:213–223
  36. Hayes AJ, Huang WQ, Yu J, Maisonpierre PC, Liu A, Kern FG, et al. Expression and function of angiopoietin-1 in breast cancer. Br J Cancer. 2000;83:1154–1160
  37. Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, Parikh AA, et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res. 2003;63:3370–3377
  38. Ding H, Roncari L, Wu X, Lau N, Shannon P, Nagy A, et al. Expression and hypoxic regulation of angiopoietins in human astrocytomas. Neuro Oncol. 2001;3:1–10
  39. Reinmuth N, Piegelbrock E, Raedel M, Fehrmann N, Hintelmann H, Wagner R, et al. Prognostic significance of vessel architecture and vascular stability in non-small cell lung cancer. Lung Cancer. 2007;55:53–60

PII: S0169-5002(09)00126-3

doi: 10.1016/j.lungcan.2009.03.002

Lung Cancer
Volume 66, Issue 3 , Pages 359-364 , December 2009

Article Tools

* Image Usage & Resolution